{"id":3660,"date":"2025-03-31T18:11:46","date_gmt":"2025-03-31T18:11:46","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/aciclovir-iv-txt\/"},"modified":"2025-03-31T18:11:46","modified_gmt":"2025-03-31T18:11:46","slug":"aciclovir-iv-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/aciclovir-iv-txt\/","title":{"rendered":"Aciclovir IV.txt"},"content":{"rendered":"

Aciclovir IV<\/h1>\n

CLINICAL USE <\/H3>Antiviral agent:Herpes simplex and herpes zoster infection

DOSE IN NORMAL RENAL FUNCTION <\/H3><\/p>\n
  • Herpes simplex treatment: normal or immunocompromised 5 mg\/kg every 8 hours\n
  • Recurrent varicella zoster infection: normal immune status 5 mg\/kg every 8 hours\n
  • Primary and recurrent varicella zoster infection: immunocompromised 10 mg\/kg every 8 hours\n
  • Herpes simplex encephalitis: normal or immunocompromised 10 mg\/kg every 8 hours<\/li>\n

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :225.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :9\u201333<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 40\u201370<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.7<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2.9\/19.5 (dialysis: 5.7)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>25\u201350 5\u201310 mg\/kg every 12 hours10\u201325 5\u201310 mg\/kg every 24 hours (some units use 3.5\u20137 mg\/kg every 24 hours)
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 2.5\u20135 mg\/kg every 24 hours

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=10\u201325 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Ciclosporin: reports of increased and decreased ciclosporin levels. Some editors report no experience of interaction locally; possibly increased risk of nephrotoxicity\n
  • Higher plasma levels of aciclovir and mycophenolate mofetil with concomitant administrationTacrolimus: possibly increased risk of nephrotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Sodium chloride 0.9% or water for injection; 10 mL to each 250 mg vial; 20 mL to 500 mg vial (Resulting solution contains 25 mg\/mL)

    Route <\/H4>IV

    Rate of Administration <\/H4>1 hour; can worsen renal impairment if injected too rapidly!

    Comments<\/H4>\n
  • Reconstituted solution may be further diluted to concentrations not greater than 5 mg\/mL\n
  • Use 100 mL infusion bags for doses of 250\u2013500 mg; use 2 \u00d7 100 mL bags for 500\u20131000 mg\n
  • Compatible with sodium chloride 0.9% and glucose 5%\n
  • DO NOT REFRIGERATE\n
  • Do not use turbid or crystal-containing solutions\n
  • Reconstituted solution very alkaline (pH 11)

    OTHER INFORMATION <\/H4>\n
  • Aciclovir clearance in CAVHD is approximately equivalent to urea clearance, i.e. lower clearance than in intermittent haemodialysis\n
  • Monitor aciclovir levels in critically ill patients. Reports of neurological toxicity at maximum recommended doses\n
  • Renal impairment developing during treatment with aciclovir usually responds rapidly to rehydration of the patient, and\/or dosage reduction or withdrawal of the drug. Adequate hydration of the patient should be maintained\n
  • Plasma aciclovir concentration is reduced by 60% during haemodialysis
    \n","protected":false},"excerpt":{"rendered":"

    Aciclovir IV CLINICAL USE Antiviral agent:Herpes simplex and herpes zoster<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3660","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3660"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3660\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}